Following Announcement of Trial Results, Decision Resources Has Reduced its Sales Forecast for Avastin by Nearly $1 Billion in 2017
Marcus Hoyle, analyst at Decision Resources is available to discuss the recently announced NSABP C-08 clinical trial results in which Roche/Chugai's monoclonal antibody Avastin* (bevacizumab) failed to meet its primary endpoint of reducing the recurrence of early-stage (adjuvant) colon cancer. As a result of this recently publicized news, Decision Resources has reduced its sales forecast for Avastin in 2017 by nearly $1 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Mr. Hoyle is available to discuss: -- The impact of this Phase III clinical trial result on sales of Avastin through 2017 in the world's major pharmaceutical markets -- Whether the results of the NSABP C-08 clinical trial may cast doubt over a second colon cancer clinical trial for Avastin, the AVANT trial, which is currently underway -- How the results of the NSABP C-08 clinical trial might affect the development of other monoclonal antibodies for early stage colon cancer treatment
To speak with Mr. Hoyle, please contact Christopher Comfort at 781-296-2597 or email@example.com.
*Avastin is marketed by Genentech, Inc. which was purchased by F. Hoffman-La Roche Ltd. in March, 2009.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Christopher Comfort 781-296-2597 firstname.lastname@example.org /PRNewswire -- April 23/
First Call Analyst:
SOURCE: Decision Resources
Web Site: http://www.decisionresources.com/